Leading German doctors criticise rising use of post-marketing observational studies by drug companiesBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b4199 (Published 13 October 2009) Cite this as: BMJ 2009;339:b4199
- Annette Tuffs
Tens of thousands of German patients treated by GPs or in specialist practices are involved in observational studies paid for by the drug industry without ever having given their consent. The companies pay doctors as much as €1000 (£925; $1475) a patient for prescribing a drug and documenting its effects. Critics say this is just a way to push new and expensive drugs that have few innovative qualities onto the market.
Carl-Heinz Müller, a GP and one …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial